The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM)
K. Naoki, H. Kunikane, H. Okamoto, N. Hida, Y. Narita, I. Nakachi, I. Kawada, H. Watanabe, H. Yasuda, K. Soejima, A. Ishizaka, K. Watanabe (Yokohama, Tokyo, Japan)
Source: Annual Congress 2006 - Screening, diagnosis, staging, prognosis, biological features
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Naoki, H. Kunikane, H. Okamoto, N. Hida, Y. Narita, I. Nakachi, I. Kawada, H. Watanabe, H. Yasuda, K. Soejima, A. Ishizaka, K. Watanabe (Yokohama, Tokyo, Japan). The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM). Eur Respir J 2006; 28: Suppl. 50, 581
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001
Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010
The diagnostic value of mucinous carcinoma - associated antigen (MCA) testin differentiation of malignant from benign pleural effusion (PE) Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004
Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003
Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Malignant pleural mesothelioma (MPM) – 5 years of experience Source: Eur Respir J 2006; 28: Suppl. 50, 91s Year: 2006
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013
Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005
Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010